Longitudinal Analysis of Drug Burden Index
NCT03024541 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9985
Last updated 2017-01-19
Summary
Anticholinergic and sedative drugs are frequently prescribed to older people, despite their negative impact on older people's physical and cognitive function. To estimate the cumulative exposure to anticholinergic and sedative drugs, Hilmer et al. published the Drug Burden Index (DBI) in 2007. The present study aims to complement previous study findings showing higher DBI values to be associated with physical and cognitive impairment. Most previously conducted studies of the DBI were either cross-sectional or were longitudinal but with short follow-ups. Furthermore, it remains unknown whether higher DBI values carry extra risks for patients with dementia. Finally, relatively little is known about the stability of DBI values over time. The current project therefore aims to examine (1) longitudinal relationships between long-term cumulative exposure to anticholinergic and sedative drugs as measured with the DBI and cognitive and physical function, (2) to examine interaction effects between DBI exposure and dementia, and (3) to examine trajectories of DBI exposure, i.e. DBI exposure remaining stable, declining, increasing or fluctuating over time. These project aims will be studied with longitudinal data from eligible participants \> 60 years from the LASA study with participants being followed-up during two decades, and the longitudinal data from the InterRAI consortium. Various clinical outcomes regarding cognitive and physical function will be studied. Data will be analysed with generalised linear mixed models and Latent Class Growth Analysis.
Conditions
- Polypharmacy
- Anticholinergics
- Hypnotics and Sedatives
- Cognitive Function
- Physical Function
Sponsors & Collaborators
-
University of Groningen
lead OTHER
Eligibility
- Min Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2016-06-30
- Primary Completion
- 2016-06-30
- Completion
- 2016-06-30
More Related Trials
-
Study of Dronabinol Treatment for Depression and/or Anxiety in Older Patients
NCT03369639 ·Status: WITHDRAWN
-
Taking Account of Inobservable Periods in Longitudinal Drug Treatment Follow-up
NCT02827331 ·Status: COMPLETED
-
Correlation Between Immune Metabolism in Patients With Benzodiazepine Poisoning and Patients'Mental Disorders
NCT05184959 ·Status: UNKNOWN
-
Association Between Intake of Psychotropic Medications and Risk of Falls in Older Adults
NCT07112573 ·Status: RECRUITING
-
Haloperidol Prophylaxis in Older Emergency Department Patients
NCT01530308 ·Status: COMPLETED ·Phase: PHASE4
-
Quantification of Drugs and Their Degradation Products
NCT01828372 ·Status: UNKNOWN ·Phase: NA
-
Evaluation of the Management of Tramadol Use Disorders
NCT04550754 ·Status: COMPLETED
-
Brief Motivational Intervention (BMI) on the Deprescription of Benzodiazepines and Related Substances in Adult Chronic Drug Users
NCT06446349 ·Status: RECRUITING ·Phase: NA
-
Prevalence of New Psychoactive Substances Use
NCT03695419 ·Status: UNKNOWN
-
The Effects of Fentanyl Abuse on Executive Function and Related Brain Activity
NCT05469217 ·Status: UNKNOWN
-
Drug Interactions With Risk of QT-prolongation in a General Hospital
NCT02043912 ·Status: COMPLETED
-
Identification of Iatrogenic Drug Events Upon Admission to the Adult Emergency Departments
NCT07333131 ·Status: RECRUITING
-
A Study to Evaluate Abuse Potential of Istradefylline
NCT02609477 ·Status: COMPLETED ·Phase: PHASE1
-
The Discriminative Effects of Tramadol in Humans
NCT00499746 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280
NCT00681746 ·Status: COMPLETED ·Phase: PHASE1
-
Clonidine vs. Dexmedetomidine in Agitated Delirium in Intensive Care Patients
NCT04758936 ·Status: UNKNOWN ·Phase: PHASE4
-
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
NCT00902772 ·Status: COMPLETED ·Phase: PHASE1
-
Current Situation on the Consumption of Hypnotic Substances at the Pharmacy
NCT02896153 ·Status: COMPLETED
-
Study to Evaluate the Abuse Potential of ACT-541468 in Healthy Recreational Drug Users
NCT03657355 ·Status: COMPLETED ·Phase: PHASE1
-
Opiates and Benzodiazepines on Driving
NCT03447353 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetic, Safety, and Tolerability Study of Intranasally Administered Esketamine in Elderly and and Healthy Younger Adult Participants
NCT02345148 ·Status: COMPLETED ·Phase: PHASE1
-
Lorazepam-Induced Toxicity in the Aged
NCT00044642 ·Status: COMPLETED ·Phase: PHASE4
-
Systemic Ketamine for the Improvement of Post-Operative Analgesia at the Alcohol-Dependent Patient
NCT00329394 ·Status: SUSPENDED ·Phase: PHASE3
-
A Study of The Abuse Liability Potential of RO4917838 in Recreational Drug Users
NCT01438749 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Long Term of Benzodiazepine Use on Psychiatric Manifestation
NCT04792658 ·Status: UNKNOWN